A Study Testing an Improved Dose of UM171 to Help Make Cord Blood Transplants More Effective and Safe.

This clinical study is testing a new way to improve stem cell transplants for adults with high-risk blood cancers, such as leukemia or myelodysplasia, who do not have a suitable donor. The transplant uses stem cells from umbilical cord blood that have been expanded in the lab using a molecule called UM171. Previous studies showed that UM171 helps these cells grow and work better, leading to faster blood count recovery and fewer complications. In this study, researchers are testing whether increasing the dose of UM171 during the lab expansion process can make the transplant less toxic. The hyp

Trial Details

NCT ID
NCT07301866
Phase
PHASE1 / PHASE2
Sponsor
Ciusss de L'Est de l'Île de Montréal
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • ECT-001-CB
Locations (sample)
  • Montreal, Quebec, Canada|45.50884,-73.58781

Key Eligibility Criteria

  • Subjects ≥ 18 and ≤ 67 years old,
  • Patient with either i. High risk acute leukemia or myelodysplasia defined as expected 2 year OS or PFS \< 40% after a conventional allogeneic HSC t…
  • Availability of an adequate CB for expansion:
  • i. ≥ 5/8 HLA match when A, B, C and DRB1 are performed at the allele level.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →